

The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

WHY IDNA?

- 1 Access to companies at the forefront of genomics and immunology innovation
- 2 Exposure to global stocks along the full value chain of genomics, immunotherapy and healthcare industries
- 3 Seek long-term growth with companies that can shape the global economic future

GROWTH OF HYPOTHETICAL 10,000 USD SINCE INCEPTION



The Growth of \$10,000 chart reflects a hypothetical \$10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

PERFORMANCE

	1 Year	3 Year	5 Year	10 Year	Since Inception
NAV	-14.27%	-15.22%	-4.55%	N/A	-2.32%
Market Price	-14.11%	-15.20%	-4.65%	N/A	-2.29%
Benchmark	-14.62%	-15.27%	-4.42%	N/A	-2.26%

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by visiting www.iShares.com or www.blackrock.com.

Beginning 8/10/20, the market price returns are calculated using the closing price.

Prior to 8/10/20, the market price returns were calculated using the midpoint of the bid/ask spread at 4:00 PM ET. The returns shown do not represent the returns you would receive if you traded shares at other times.

KEY FACTS

Fund Launch Date	06/11/2019
Benchmark	NYSE FactSet Global Genomics and Immuno Biopharma Index (USD)
30 Day SEC Yield	0.85%
Number of Holdings	51
Net Assets	\$108,417,251

Ticker	IDNA
CUSIP	46435U192
Exchange	NYSE Arca

TOP HOLDINGS (%)

BEIGENE LTD	6.57
SANOFI SA	5.54
ROCHE HOLDING PAR AG	5.49
GLAXOSMITHKLINE	5.40
ASTRAZENECA PLC	5.24
EXELIXIS INC	5.05
TAKEDA PHARMACEUTICAL LTD	4.95
SPRINGWORKS	
THERAPEUTICS INC	4.73
GENMAB	4.33
MERCK & CO INC	4.26
	51.56

Holdings are subject to change.


TOP SECTORS (%)

Health Care	99.09%
Cash and/or Derivatives	0.57%
Materials	0.34%

FUND CHARACTERISTICS

Beta vs. S&P 500 (3y)	1.10
Standard Deviation (3yrs)	24.06%
Price to Earnings	22.10
Price to Book Ratio	2.28

GEOGRAPHIC BREAKDOWN (%)



FEES AND EXPENSES BREAKDOWN

Expense Ratio	0.47%
Management Fee	0.47%
Acquired Fund Fees and Expenses	0.00%
Foreign Taxes and Other Expenses	0.00%

GLOSSARY

Beta is a measure of the tendency of securities to move with the market as a whole. A beta of 1 indicates that the security's price will move with the market. A beta less than 1 indicates the security tends to be less volatile than the market, while a beta greater than 1 indicates the security is more volatile than the market.

The price to earnings ratio (P/E) is a fundamental measure used to determine if an investment is valued appropriately. Each holding's P/E is the latest closing price divided by the latest fiscal year's earnings per share. Negative P/E ratios are excluded from this calculation. For hedged funds, the underlying fund's value is shown.

The price to book (P/B) value ratio is a fundamental measure used to determine if an investment is valued appropriately. The book value of a company is a measure of how much a company's assets are worth assuming the company's debts are paid off. Each holding's P/B is the latest closing price divided by the latest fiscal year's book value per share. Negative book values are excluded from this calculation. For hedged funds, the underlying fund's value is shown.

Want to learn more?

www.iShares.com



www.blackrockblog.com



@iShares

Carefully consider the Fund's investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Fund's prospectus, and if available, summary prospectus, which may be obtained by calling 1-800-iShares (1-800-474-2737) or by visiting www.iShares.com or www.blackrock.com. Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/developing markets and in concentrations of single countries. Funds that concentrate investments in specific industries, sectors, markets or asset classes may under-perform or be more volatile than other industries, sectors, markets or asset classes than the general securities market.

Companies in the healthcare sector may be affected by government regulations and programs, changes in the cost of medical products and services, changes in the demand for medical products and services among other factors. Healthcare companies are subject to competitive forces that may result in product obsolescence.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

Diversification may not protect against market risk or loss of principal. Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the fund. Any applicable brokerage commissions will reduce returns.

Index returns are for illustrative purposes only. Index performance returns do not reflect any management fees, transaction costs or expenses.

Indexes are unmanaged and one cannot invest directly in an index. Past performance does not guarantee future results.

"Acquired Fund Fees and Expenses" reflect the Fund's pro rata share of the indirect fees and expenses incurred by investing in one or more acquired funds, such as mutual funds, business development companies, or other pooled investment vehicles. AFEE are reflected in the prices of the acquired funds and thus included in the total returns of the Fund.

The iShares Funds are distributed by BlackRock Investments, LLC (together with its affiliates, "BlackRock").

BlackRock provides compensation in connection with obtaining or using third-party ratings and rankings.

© 2025 BlackRock, Inc. or its affiliates. All rights reserved. **iSHARES**, **iBONDS** and **BLACKROCK** are trademarks of BlackRock, Inc. or its affiliates. All other trademarks are those of their respective owners.

FOR MORE INFORMATION, VISIT WWW.ISHARES.COM OR CALL 1-800 ISHARES (1-800-474-2737)

iS-IDNA-F0325

Not FDIC Insured - No Bank Guarantee - May Lose Value

1879050

BLACKROCK®



SUSTAINABILITY CHARACTERISTICS

Sustainability Characteristics provide investors with specific non-traditional metrics. Alongside other metrics and information, these enable investors to evaluate funds on certain environmental, social and governance characteristics. Sustainability Characteristics do not provide an indication of current or future performance nor do they represent the potential risk and reward profile of a fund. They are provided for transparency and for information purposes only. Sustainability Characteristics should not be considered solely or in isolation, but instead are one type of information that investors may wish to consider when assessing a fund.

This fund does not seek to follow a sustainable, impact or ESG investment strategy. The metrics do not change the fund's investment objective or constrain the fund's investable universe, and there is no indication that a sustainable, impact or ESG investment strategy will be adopted by the fund. For more information regarding the fund's investment strategy, please see the fund's prospectus.

MSCI ESG Fund Rating (AAA-CCC)	BBB	MSCI ESG Quality Score (0-10)	5.23
MSCI ESG Quality Score - Peer Percentile	12.77%	MSCI ESG % Coverage	94.42%
Fund Lipper Global Classification	Equity Sector Healthcare	MSCI Weighted Average Carbon Intensity (Tons CO2E/\$M SALES)	34.02
Funds in Peer Group	509	MSCI Weighted Average Carbon Intensity % Coverage	94.07%

All data is from MSCI ESG Fund Ratings as of **20-Jan-2025**, based on holdings as of **30-Nov-2024**. As such, the fund's sustainable characteristics may differ from MSCI ESG Fund Ratings from time to time.

To be included in MSCI ESG Fund Ratings, 65% (or 50% for bond funds and money market funds) of the fund's gross weight must come from securities with ESG coverage by MSCI ESG Research (certain cash positions and other asset types deemed not relevant for ESG analysis by MSCI are removed prior to calculating a fund's gross weight; the absolute values of short positions are included but treated as uncovered), the fund's holdings date must be less than one year old, and the fund must have at least ten securities.

ESG GLOSSARY:

MSCI ESG Fund Rating (AAA-CCC): The MSCI ESG Rating is calculated as a direct mapping of ESG Quality Scores to letter rating categories (e.g. AAA = 8.6-10). The ESG Ratings range from leader (AAA, AA), average (A, BBB, BB) to laggard (B, CCC).

MSCI ESG Quality Score - Peer Percentile: The fund's ESG Percentile compared to its Lipper peer group.

Fund Lipper Global Classification: The fund peer group as defined by the Lipper Global Classification.

Funds in Peer Group: The number of funds from the relevant Lipper Global Classification peer group that are also in ESG coverage.

MSCI ESG Quality Score (0-10): The MSCI ESG Quality Score (0 - 10) for funds is calculated using the weighted average of the ESG scores of fund holdings. MSCI rates underlying holdings according to their exposure to industry specific ESG risks and their ability to manage those risks relative to peers.

MSCI ESG % Coverage: Percentage of the fund's holdings for which the MSCI ESG ratings data is available. The MSCI ESG Fund Rating, MSCI ESG Quality Score and MSCI ESG Quality Score – Peer Percentile metrics are displayed for funds with at least 65% coverage (or 50% for bond funds and money market funds).

MSCI Weighted Average Carbon Intensity (Tons CO2E/\$M SALES): Measures a fund's exposure to carbon intensive companies. This figure represents the estimated greenhouse gas emissions per \$1 million in sales across the fund's holdings. This allows for comparisons between funds of different sizes.

MSCI Weighted Average Carbon Intensity % Coverage: Percentage of the fund's holdings for which MSCI Carbon Intensity data is available. The MSCI Weighted Average Carbon Intensity metric is displayed for funds with any coverage. Funds with low coverage may not fully represent the fund's carbon characteristics given the lack of coverage.

Certain information contained herein (the "Information") has been provided by MSCI ESG Research LLC, a RIA under the Investment Advisers Act of 1940, and may include data from its affiliates (including MSCI Inc. and its subsidiaries ("MSCI")), or third party suppliers (each an "Information Provider"), and it may not be reproduced or disseminated in whole or in part without prior written permission. The Information has not been submitted to, nor received approval from, the US SEC or any other regulatory body. The Information may not be used to create any derivative works, or in connection with, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between equity index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. Neither MSCI ESG Research nor any Information Party makes any representations or express or implied warranties (which are expressly disclaimed), nor shall they incur liability for any errors or omissions in the Information, or for any damages related thereto. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.



ARKG

ARK GENOMIC REVOLUTION ETF



ARK
INVEST

ETFs

WHY INVEST IN ARKG?



Exposure to Innovation: Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations.



Growth Potential: Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.



Tool for Diversification: Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.



Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.




Cost Effective: Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.

FUND DETAILS

As of March 31, 2025

Ticker	ARKG
Type	Active Equity ETF
CUSIP	00214Q302
ISIN	US00214Q3020
Primary Exchange	Cboe BZX
Inception Date	2014-10-31
Expense Ratio	0.75%
Fund AUM	\$942.8 Million
Advisor	ARK Investment Management LLC
Fund Distributor	Foreside Fund Services, LLC
Number of Holdings	40-60
Weighted Avg. Market Cap.	9 Billion
Median Market Cap.	1 Billion
Active Share (S&P500)	99%

GROWTH OF 10,000 USD SINCE INCEPTION



The line graph represents the cumulative performance of a hypothetical \$10,000 investment. The returns are net of the ETF's expenses but do not reflect the payment of any brokerage commissions or brokerage costs incurred as a result of buying or selling fund shares and do not reflect the deduction of taxes to which an investor would be subject as a result of owning or selling shares of the fund. If they did, the returns would be lower than those shown.

FUND PERFORMANCE

For periods ended March 31, 2025

	1 Month	3 Months	YTD	1 Year	3 Years	5 Years	10 Years	Since Inception
ARKG NAV	-15.58%	-11.93%	-11.93%	-27.84%	-23.31%	-7.66%	-0.08%	1.12%
ARKG Market Price	-15.68%	-11.81%	-11.81%	-27.82%	-23.26%	-7.60%	-0.14%	1.11%
NASDAQ Biotech. Index [XNBI]	-5.98%	-1.31%	-1.31%	-3.39%	1.46%	5.39%	2.30%	3.67%
S&P 500 Index [SPX]	-5.63%	-4.27%	-4.27%	8.25%	9.06%	18.59%	12.50%	12.43%
MSCI World Index [M1WO]	-4.45%	-1.79%	-1.79%	7.04%	7.58%	16.13%	9.50%	9.49%

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares when redeemed may be worth more or less than the original cost. For the Fund's most recent month end performance, please visit www.ark-funds.com or call 1-800-679-7759. Returns for less than one year are not annualized. Net asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the Cboe BZX Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.

FUND OBJECTIVE

ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution. Companies within ARKG are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

TOP 10 HOLDINGS

As of March 31, 2025

	SECURITY NAME	WEIGHT
1	Twist Bioscience Corp	9.2%
2	Tempus AI Inc	8.2%
3	CRISPR Therapeutics AG	7.4%
4	Recursion Pharmaceuticals Inc	6.9%
5	Guardant Health Inc	6.2%
6	Natera Inc	5.9%
7	Adaptive Biotechnologies Corp	5.9%
8	Schrodinger Inc/United States	4.6%
9	CareDx Inc	4.3%
10	Beam Therapeutics Inc	4.2%
		62.8%

Holdings are subject to change. For current portfolio holdings please download "Fund Holdings" as a CSV or PDF at ark-funds.com. Portfolio holdings should not be considered as investment advice or a recommendation to buy, sell or hold any particular security. The securities identified do not represent all of the securities purchased, sold or recommended for client accounts. It should not be assumed that an investment in the securities identified was or will be profitable.

TECHNOLOGY BREAKDOWN

Multiomic Technologies	42.1%
Precision Therapies	31.2%
Programmable Biology	13.0%
Neural Networks	8.5%
Next Gen Cloud	2.7%
Humanoid Robots	1.7%
Intelligent Devices	0.8%

MARKET CAPITALIZATION

Mega (\$100B+)	3.2%
Large (\$10 - \$100B)	10.4%
Medium (\$2 - \$10B)	44.9%
Small (\$300M - \$2B)	34.6%
Micro (\$50 - \$300M)	6.7%

SECTOR BREAKDOWN

Health Care	98.6%
Information Technology	1.3%

GEOGRAPHIC BREAKDOWN

North America	92.1%
Western Europe	7.9%

Holdings are subject to change. The Technology Breakdown is based on ARK's internal thematic research elements and portfolio company classification. Geographic Breakdown relates principally to the domicile of the issuers of the securities held in the ETF. Sector Breakdown is based on the Bloomberg Industry Classification System (BICS).

Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus and summary prospectus, a copy of which may be obtained by visiting www.ark-funds.com. Please read the prospectus and summary prospectus carefully before you invest.

The principal risks of investing in ARKG: **Equity Securities Risk.** The value of the equity securities the Fund holds may fall due to general market and economic conditions. **Foreign Securities Risk.** Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. **Health Care Sector Risk.** The health care sector may be adversely affected by government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration of a patent may adversely affect their profitability. **Biotechnology Company Risk.** A biotechnology company's valuation can often be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities. **Pharmaceutical Company Risk.** Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Detailed information regarding the specific risks of ARKG can be found in the ETF's prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification risks, as well as fluctuations in market value and NAV. An investment in an ETF is subject to risks and you can lose money on your investment in an ETF. There can be no assurance that the ETF will achieve its investment objective. The ETF's portfolio is more volatile than broad market averages. Shares of ARKG are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

The Adviser expects to invest at least 80% of the Fund's assets in Genomics Revolution Companies. However, certain of these companies do not currently derive a substantial portion of their current revenues from genomic-focused businesses and there is no assurance that any company will do so in the future, which may adversely affect the ability of the Fund to achieve its investment objective.

Index Descriptions: The S&P 500® Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. The MSCI World Index represents large and mid-cap equity performance across 23 developed markets countries. Returns shown for the MSCI World Index are net of foreign withholding taxes applicable to U.S. investors. Securities in the ETF's portfolio will not match those in any index. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. The ETF is benchmark agnostic and corresponding portfolios may have significant non-correlation to any index. Index returns are generally provided as an overall market indicator. You cannot invest directly in an index. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index's returns. Index performance information was furnished by sources deemed reliable and is believed to be accurate, however, no warranty or representation is made as to the accuracy thereof and the information is subject to correction.

Glossary: **Active Share** is a measure of the percentage of stock holdings in a manager's portfolio that differ from the benchmark index. **Value Strategy:** Traditional value investing is an investment strategy where stocks are selected that trade for less than their intrinsic values. **Growth Strategy:** Traditional growth investing is an investment strategy that focuses on stocks, whose earnings are expected to grow at an above-average rate compared to its industry or the overall market. **Correlation:** The degree to which two strategies move in relation to each other.

Foreside Fund Services LLC, distributor.

NOT FDIC INSURED - NO BANK GUARANTEE - MAY LOSE VALUE